Celcuity (CELC) Retained Earnings (2016 - 2026)
Celcuity's (CELC) quarterly Retained Earnings came in at -$448.9 million in Q4 2025, down 65.12% YoY from -$1.3 billion in Q4 2024, and down 12.81% on a QoQ basis from -$397.9 million in Q3 2025.
Analysis
Celcuity (CELC) Retained Earnings (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Retained Earnings data on file, last reported at -$448.9 million in Q4 2025.
- Quarterly Retained Earnings fell 65.12% year-over-year to -$448.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$448.9 million (down 65.12% YoY) and the FY2025 annual result came in at -$448.9 million, down 65.12% from the prior year.
- Retained Earnings eased to -$448.9 million in Q4 2025, from -$397.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $398.5 million in Q2 2025 to a low of -$448.9 million in Q4 2025.
- A 5-year average of -$57.6 million and a median of -$79.3 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings tumbled 231.05% — and 2022, when it surged 511.33%.
- Tracing CELC's Retained Earnings over 5 years: stood at -$55.9 million in 2021, then surged by 511.33% to $230.0 million in 2022, then plunged by 169.58% to -$160.1 million in 2023, then slumped by 69.83% to -$271.9 million in 2024, then tumbled by 65.12% to -$448.9 million in 2025.
- The last three Retained Earnings figures came in at -$448.9 million (Q4 2025), -$397.9 million (Q3 2025), and $398.5 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | -580.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -580.60 Mn |
| Dec 31, 2025 | 549.40 Mn |
| Sep 30, 2025 | 514.84 Mn |
| Jun 30, 2025 | 398.46 Mn |
| Mar 31, 2025 | 395.48 Mn |
| Dec 31, 2024 | 387.44 Mn |
| Sep 30, 2024 | 384.87 Mn |
| Jun 30, 2024 | 382.06 Mn |
| Mar 31, 2024 | 315.39 Mn |
| Dec 31, 2023 | 299.82 Mn |
| Sep 30, 2023 | 234.10 Mn |
| Jun 30, 2023 | 232.93 Mn |
| Mar 31, 2023 | 231.44 Mn |
| Dec 31, 2022 | 230.05 Mn |
| Sep 30, 2022 | 128.23 Mn |
| Jun 30, 2022 | 127.00 Mn |
| Mar 31, 2022 | 125.39 Mn |
| Dec 31, 2021 | 124.62 Mn |
| Sep 30, 2021 | 123.63 Mn |
| Jun 30, 2021 | 70.17 Mn |